Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 15 Jun 2018
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Nivolumab (Primary)
- Indications Neuroendocrine tumours; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 27 Dec 2017 Status changed from not yet recruiting to recruiting.
- 02 Nov 2017 New trial record